GP350 CAR-T

Phase 2Cell therapy

ZZhimin Zhai

GP350 CAR-T is one of 7 biologic programs targeting Epstein-Barr virus infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epstein-Barr Virus InfectionRecruiting

Epstein-Barr Virus InfectionPhase 2

Recruiting

Competition

Competitive Landscape

8 competitors in Epstein-Barr Virus Infection

#DrugCompanyPhaseTrials

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Taxol

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Adrucil

Gemzar

GGynecologic Oncology Group

GP350 CAR-T

1 7

Mrna-1195

Moderna

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 1/2Recruiting

Epstein-Barr Virus Infection

NCT07306156

Clinical

Trials by Indication[1]

Epstein-Barr virus infection1 trial

GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms

Recruiting·ZZhimin Zhai·Phase 1/2·NCT07306156·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GP350 CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GP350 CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GP350 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhimin Zhai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: ZZhimin Zhai

GP350 CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Epstein-Barr virus infection1 trial

References

Drug Info

Quick Facts

Related News